Trial Profile
Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Pancreatic cancer; Solid tumours
- Focus Therapeutic Use
- 16 Feb 2017 Status changed from recruiting to completed.
- 01 Jun 2015 New trial record